U.S. signs $1.2 billion deal for 1.7 million courses of Merck’s experimental COVID-19 drug

World45 minutes ago (Jun 09, 2021 09:21AM ET)

(C) Reuters. FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid

(Reuters) -Merck & Co Inc said on Wednesday the U.S. government has agreed to pay about $1.2 billion for 1.7 million courses of its experimental COVID-19 treatment, if it is proven to work in an ongoing large trial and authorized by U.S. regulators.

The oral antiviral treatment, molnupiravir, aims to stop COVID-19 from progressing and can be given early in the course of the disease, similar to Tamiflu to treat influenza.

The treatment course being tested in the trial is an oral dose given every 12 hours for five days.

Merck expects to have more than 10 million courses of the therapy available by the end of this year and said it was in discussions with other countries interested in advance purchase agreements for molnupiravir.

The company, which is developing the drug with Ridgeback Biotherapeutics, is assessing the treatment in a late-stage trial in non-hospitalized patients to see if it reduces the risk of hospitalization or death.

Data from the trial, which plans to enroll a total of 1,850 patients globally, are expected in the fall of 2021, according to the U.S. Department of Health and Human Services.

Other antiviral drugs also contending to be the first treatment aimed at the cause of COVID-19 include Pfizer Inc (NYSE:PFE)’s PF-07321332 and Roche Holding AG (OTC:RHHVF)’s AT-527.

If successful, Merck said it expects to file for the emergency use authorization of molnupiravir in the second half of 2021 at the earliest.

Merck has focused on its treatment after two COVID-19 vaccines it was developing failed to generate the necessary immune responses in early testing, prompting it to abandon them in January.

The drugmaker announced a change of plans and said in April it would no longer pursue use of molnupiravir in hospitalized patients.

U.S. signs $1.2 billion deal for 1.7 million courses of Merck’s experimental COVID-19 drug

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Stories

Discover

Tennis-Unseeded Krejcikova wins maiden Grand Slam title in Paris

World38 minutes ago (Jun 12, 2021 12:26PM ET) 6/6 (C) Reuters. Tennis - French Open -...

Biden to hold solo news conference after Putin summit

World54 minutes ago (Jun 12, 2021 12:10PM ET) (C) Reuters. FILE PHOTO: U.S. President Joe...

Apple’s iPadOS 15 breaks the app barrier

The announcement of new iPad software at this year’s WWDC conference had an abnormally...

7 new security features Apple quietly announced at WWDC

Apple went big on privacy during its Worldwide Developer Conference (WWDC) keynote this week,...

This Week in Apps: WWDC 21 highlights, Instagram Creator...

Welcome back to This Week in Apps, the weekly TechCrunch series that recaps the latest in mobile...

Popular Categories